At ADMdx, we are advancing the diagnosis and treatment of Alzheimer’s disease and other brain disorders.  Applying our expertise and AI to brain images and other biomarkers, we are translating the brain’s intricacy into new insights for medical professionals, patients, and those development treatments.

Our image analysis reports, clinical trial services, and research are being used in the diagnosis and drug development for Alzheimer’s disease, Parkinson’s disease, Traumatic Brain Injury, and other disorders. Powered by technology, the constant focus of our innovation is the patients, physicians, and partners whom we serve.

Alzheimer’s disease and other disorders can have devastating effects over time on the way people are able to think and function. Yet, the cause of disease is often misdiagnosed or not detected until symptoms have become obvious. Earlier, accurate detection can lead to better treatment, the ability to plan, and peace of mind.

Standard brain images hold information that is not readily detected and too complex to be clinically meaningful. Yet, these many subtle changes in tissue volume, function, or composition can reveal the cause of disease and inform prognosis when put into context.

With extensive data, proprietary curation, and cutting-edge pattern analysis methods, ADMdx translates image data to clinical insight. With our differentiated expertise, technology, and focus on quality and the end user, we are producing a pipeline of products and services that can truly make a difference.